- Home
- CSWC vs ELVN Comparison
CSWC vs ELVN Comparison
Compare CSWC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSWC
- ELVN
- Stock Information
- Founded
- CSWC 1961
- ELVN 2016
- Country
- CSWC United States
- ELVN United States
- Employees
- CSWC N/A
- ELVN N/A
- Industry
- CSWC Textiles
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- CSWC Consumer Discretionary
- ELVN Health Care
- Exchange
- CSWC Nasdaq
- ELVN Nasdaq
- Market Cap
- CSWC 1.2B
- ELVN 1.2B
- IPO Year
- CSWC N/A
- ELVN 2020
- Fundamental
- Price
- CSWC $23.36
- ELVN $22.63
- Analyst Decision
- CSWC Buy
- ELVN Strong Buy
- Analyst Count
- CSWC 4
- ELVN 5
- Target Price
- CSWC $23.25
- ELVN $41.20
- AVG Volume (30 Days)
- CSWC 646.1K
- ELVN 730.4K
- Earning Date
- CSWC 08-04-2025
- ELVN 08-12-2025
- Dividend Yield
- CSWC 11.02%
- ELVN N/A
- EPS Growth
- CSWC N/A
- ELVN N/A
- EPS
- CSWC 1.47
- ELVN N/A
- Revenue
- CSWC $204,439,000.00
- ELVN N/A
- Revenue This Year
- CSWC $13.04
- ELVN N/A
- Revenue Next Year
- CSWC $12.23
- ELVN N/A
- P/E Ratio
- CSWC $15.83
- ELVN N/A
- Revenue Growth
- CSWC 14.77
- ELVN N/A
- 52 Week Low
- CSWC $17.46
- ELVN $13.30
- 52 Week High
- CSWC $27.23
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- CSWC 75.03
- ELVN 60.45
- Support Level
- CSWC $22.58
- ELVN $19.38
- Resistance Level
- CSWC $22.22
- ELVN $21.34
- Average True Range (ATR)
- CSWC 0.37
- ELVN 1.27
- MACD
- CSWC 0.12
- ELVN 0.11
- Stochastic Oscillator
- CSWC 94.61
- ELVN 88.47
About CSWC Capital Southwest Corporation
Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.